Listed

Kymera Therapeutics, Inc.

KYMRNasdaqCIK 1815442HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$65.0mRevenue, Q2 FY2026, three months to 2026-06-30$65.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 5, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$65.0mRevenue, Q2 FY2026, three months to 2026-06-30$65.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure+466.4% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin−116.3%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$75.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Revenue: $65.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure+620.5 pts on a year earlier
  • Net margin−94.2%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$61.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Revenue: $65.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure+573.4 pts on a year earlier
  • Diluted EPS−$0.62Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure+34.7% on a year earlier
  • Free cash flow−$54.5mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$54.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001193125-26-333849. Derived: 6-month figure less the 3-month figure.Capital expenditure: $473.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001193125-26-333849. Derived: 6-month figure less the 3-month figure.Report this figure+10.0% on a year earlier

Last eight quarters

Full statements
Revenue$65.0mOperating margin −116.3%
Diluted EPS−$0.62, Q2 FY2026
Free cash flow−$54.5m, Q2 FY2026
Kymera Therapeutics, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m3.7Revenue, Q3 FY2024, three months to 2024-09-30$3.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figure7.4Revenue, Q4 FY2024, three months to 2024-12-31$7.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Report this figure22.1Revenue, Q1 FY2025, three months to 2025-03-31$22.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure11.5Revenue, Q2 FY2025, three months to 2025-06-30$11.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure2.8Revenue, Q3 FY2025, three months to 2025-09-30$2.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figure2.9Revenue, Q4 FY2025, three months to 2025-12-31$2.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Report this figure34.4Revenue, Q1 FY2026, three months to 2026-03-31$34.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure65.0Revenue, Q2 FY2026, three months to 2026-06-30$65.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(1927.9%)Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$72.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Revenue: $3.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figure(1092.2%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$80.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Revenue: $7.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Report this figure(336.8%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$74.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Revenue: $22.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure(736.8%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$84.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Revenue: $11.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure(3347.4%)Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: −$92.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Revenue: $2.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figure(3411.0%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$97.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Revenue: $2.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Report this figure(244.9%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$84.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Revenue: $34.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure(116.3%)Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$75.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Revenue: $65.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure
Net margin%(1670.3%)Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: −$62.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Revenue: $3.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figure(956.9%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$70.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Revenue: $7.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Report this figure(296.7%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$65.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Revenue: $22.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure(667.6%)Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$76.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Revenue: $11.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure(2973.0%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$82.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Revenue: $2.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figure(3030.7%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$87.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Revenue: $2.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Report this figure(201.5%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$69.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Revenue: $34.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure(94.2%)Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$61.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Revenue: $65.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure
Diluted EPS$ per share(0.82)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.82 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figurenot reported (Diluted EPS not reported)(0.82)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.82 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure(0.95)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.95 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure(0.94)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.94 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-04, accession 0001193125-25-263550.Report this figurenot reported (Diluted EPS not reported)(0.71)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.71 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure(0.62)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-05, accession 0001193125-26-333849.Report this figure
Free cash flow$m(50.4)Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$50.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-04, accession 0001193125-25-263550. Derived: 9-month figure less the 6-month figure.Capital expenditure: −$189.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-04, accession 0001193125-25-263550. Derived: 9-month figure less the 6-month figure.Report this figure(62.7)Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$61.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Capital expenditure: $936.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Report this figure(79.6)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$79.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Capital expenditure: $467.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure(60.6)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$59.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001193125-26-333849. Derived: 6-month figure less the 3-month figure.Capital expenditure: $695.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001193125-26-333849. Derived: 6-month figure less the 3-month figure.Report this figure(27.3)Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$27.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-04, accession 0001193125-25-263550. Derived: 9-month figure less the 6-month figure.Capital expenditure: $181.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-04, accession 0001193125-25-263550. Derived: 9-month figure less the 6-month figure.Report this figure(66.9)Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$66.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Capital expenditure: $106.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001193125-26-073395. Derived: 12-month figure less the 9-month figure.Report this figure(89.3)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$88.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Capital expenditure: $434.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-04-30, accession 0001193125-26-193967.Report this figure(54.5)Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$54.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-05, accession 0001193125-26-333849. Derived: 6-month figure less the 3-month figure.Capital expenditure: $473.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-05, accession 0001193125-26-333849. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$39.2mOperating margin −891.1%
Diluted EPS−$3.69, FY2025
Free cash flow−$234.3m, FY2025
Kymera Therapeutics, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m72.8Revenue, FY2021, twelve months to 2021-12-31$72.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-22, accession 0000950170-24-018414.Report this figure46.8Revenue, FY2022, twelve months to 2022-12-31$46.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-27, accession 0000950170-25-028355.Report this figure78.6Revenue, FY2023, twelve months to 2023-12-31$78.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-073395.Report this figure47.1Revenue, FY2024, twelve months to 2024-12-31$47.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-073395.Report this figure39.2Revenue, FY2025, twelve months to 2025-12-31$39.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-073395.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(138.0%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −$100.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-22, accession 0000950170-24-018414.Revenue: $72.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-22, accession 0000950170-24-018414.Report this figure(344.4%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −$161.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-27, accession 0000950170-25-028355.Revenue: $46.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-27, accession 0000950170-25-028355.Report this figure(210.6%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$165.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-073395.Revenue: $78.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-073395.Report this figure(555.8%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$261.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-073395.Revenue: $47.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-073395.Report this figure(891.1%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$349.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-073395.Revenue: $39.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-073395.Report this figure
Net margin%(137.6%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −$100.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-22, accession 0000950170-24-018414.Revenue: $72.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-22, accession 0000950170-24-018414.Report this figure(330.6%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$154.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-27, accession 0000950170-25-028355.Revenue: $46.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-27, accession 0000950170-25-028355.Report this figure(187.0%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$147.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-073395.Revenue: $78.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-073395.Report this figure(475.6%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$223.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-073395.Revenue: $47.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-073395.Report this figure(794.0%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$311.4m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-073395.Revenue: $39.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-073395.Report this figure
Diluted EPS$ per share(2.09)Diluted EPS, FY2021, twelve months to 2021-12-31−$2.09 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-22, accession 0000950170-24-018414.Report this figure(2.87)Diluted EPS, FY2022, twelve months to 2022-12-31−$2.87 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-27, accession 0000950170-25-028355.Report this figure(2.52)Diluted EPS, FY2023, twelve months to 2023-12-31−$2.52 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001193125-26-073395.Report this figure(2.98)Diluted EPS, FY2024, twelve months to 2024-12-31−$2.98 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001193125-26-073395.Report this figure(3.69)Diluted EPS, FY2025, twelve months to 2025-12-31−$3.69 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001193125-26-073395.Report this figure
Free cash flow$m(131)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −$128.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-22, accession 0000950170-24-018414.Capital expenditure: $1.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-22, accession 0000950170-24-018414.Report this figure(156)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −$153.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-27, accession 0000950170-25-028355.Capital expenditure: $2.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-27, accession 0000950170-25-028355.Report this figure(137)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$102.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-073395.Capital expenditure: $34.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001193125-26-073395.Report this figure(207)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$194.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-073395.Capital expenditure: $12.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001193125-26-073395.Report this figure(234)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$232.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-073395.Capital expenditure: $1.4m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001193125-26-073395.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Kymera Therapeutics, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
FMR LLC2026-06-30$1.42bn12,349,256Added+649,306
BAKER BROS. ADVISORS LP2026-06-30$992.7m8,657,242Unchanged
Avoro Capital Advisors LLC2026-06-30$857.1m7,474,747Unchanged
BlackRock, Inc.2026-06-30$635.1m5,538,210Added+477,334
BVF INC/IL2026-06-30$444.0m3,872,052Reduced−1,630,658
WELLINGTON MANAGEMENT GROUP LLP2026-06-30$421.4m3,675,028Reduced−214,659
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$343.1m2,992,193Added+118,137
Siren, L.L.C.2026-06-30$336.7m2,935,830Reduced−251,000
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$336.3m2,932,378Added+52,054
Atlas Venture Life Science Advisors, LLC2026-06-30$326.5m2,847,541Reduced−1,730,467

Recent filings

All 640 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Kymera Therapeutics, Inc., recent filings
FiledFormWhat it isAccession number
2026-10-2907:10 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001193125-26-436965
2026-08-0507:15 ET10-QQuarterly reportPeriod 2026-06-300001193125-26-333849
2026-08-0507:10 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001193125-26-333834
2026-07-2716:10 ET8-K5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-26-318078
2026-06-2618:43 ETSCHEDULE 13D/AOwnership report, active investor, amended0000921895-26-001687
2026-06-2507:10 ET8-K7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0001193125-26-281817
2026-06-2416:07 ET8-K5.07 Shareholder vote results0001193125-26-281051
2026-06-0816:05 ET8-K5.02 Departure or appointment of officers or directors0001193125-26-261698
2026-04-3007:15 ET10-QQuarterly reportPeriod 2026-03-310001193125-26-193967
2026-04-3007:10 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001193125-26-193957

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 26, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, locked when the 8-K was accepted. It is scored when the 10-Q or 10-K is ingested.See the target

About the filer

CIK
1815442
Tickers
KYMR
Exchange
Nasdaq
SIC code
2836 Biological Products, (No Diagnostic Substances)
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Large accelerated filer
Former names
Kymera Therapeutics, Inc. (to 2026-10-29)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 07:17 ET. Listed shows no prices and gives no investment advice.